- Home
- MVSTW vs RLAY Comparison
MVSTW vs RLAY Comparison
Compare MVSTW & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVSTW
- RLAY
- Stock Information
- Founded
- MVSTW 2006
- RLAY 2015
- Country
- MVSTW United States
- RLAY United States
- Employees
- MVSTW 1921
- RLAY N/A
- Industry
- MVSTW Industrial Machinery/Components
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVSTW Miscellaneous
- RLAY Health Care
- Exchange
- MVSTW Nasdaq
- RLAY Nasdaq
- Market Cap
- MVSTW N/A
- RLAY 576.1M
- IPO Year
- MVSTW N/A
- RLAY 2020
- Fundamental
- Price
- MVSTW $0.31
- RLAY $3.63
- Analyst Decision
- MVSTW
- RLAY Strong Buy
- Analyst Count
- MVSTW 0
- RLAY 11
- Target Price
- MVSTW N/A
- RLAY $18.40
- AVG Volume (30 Days)
- MVSTW 126.0K
- RLAY 1.5M
- Earning Date
- MVSTW 03-14-2025
- RLAY 08-05-2025
- Dividend Yield
- MVSTW N/A
- RLAY N/A
- EPS Growth
- MVSTW N/A
- RLAY N/A
- EPS
- MVSTW N/A
- RLAY N/A
- Revenue
- MVSTW $370,989,000.00
- RLAY $7,679,000.00
- Revenue This Year
- MVSTW N/A
- RLAY $17.59
- Revenue Next Year
- MVSTW N/A
- RLAY N/A
- P/E Ratio
- MVSTW N/A
- RLAY N/A
- Revenue Growth
- MVSTW 39.03
- RLAY N/A
- 52 Week Low
- MVSTW $0.35
- RLAY $1.78
- 52 Week High
- MVSTW $0.44
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- MVSTW N/A
- RLAY 57.25
- Support Level
- MVSTW N/A
- RLAY $3.50
- Resistance Level
- MVSTW N/A
- RLAY $3.86
- Average True Range (ATR)
- MVSTW 0.00
- RLAY 0.18
- MACD
- MVSTW 0.00
- RLAY 0.02
- Stochastic Oscillator
- MVSTW 0.00
- RLAY 65.79
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).